BioSpace News Archive

Biom’up SA, specializing in surgical hemostasis, announced a change in the Company’s leadership position.

Ultragenyx Pharmaceutical Inc. announced that it will present at the following upcoming investor conferences

Amarantus Bioscience Holdings, Inc. released a letter to shareholders from President & CEO Gerald E. Commission

Molecular Health (MH), a leading company in the field of data science for precision medicine, today announced that the Company has signed up the HudsonAlpha Institute for Biotechnology (HudsonAlpha) as a new client for MH Guide.

Apexian Pharmaceuticals, Inc. announced that it will report clinical data from its clinical study, APX-CLN-0011: A Phase 1 Study of APX3330 in Patients with Advanced Solid Tumors in a poster being presented on June 1 at the 2019 Annual Meeting of the American Society of Clinical Oncology in Chicago, Illinois.

Talaris Therapeutics, Inc. is presenting new data from its Phase 2 trial of FCR001 in living donor kidney transplant recipients in a poster at the 2019 American Transplant Congress in Boston.

First-in-human results presented for DS-1062, an investigational TROP2 targeting ADC, in patients with advanced NSCLC where no standard treatment is available

22% of Patients Receiving LYNPARZA Remained Progression-Free After Two Years vs. 10% on Placebo, Following Platinum-Based Chemotherapy

Spectrum Pharmaceuticals, Inc. announced integrated analysis results from two Phase 3 clinical trials of ROLONTIS.

The Biotechnology Institute announced the winner of the BioGENEius Hall of Fame Award, who will be recognized next week at the 2019 BIO International Convention in Philadelphia.